News Agency
The Times

Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610

  • Written by PR Newswire
Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610

TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has recently completed the first batch of subject enrollment for its novel adjuvanted recombinant shingles vaccine, REC610.

The study is a randomized,...

Read more: Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion